Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2022 financial results on May 10, 2022, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2022 financial results on May 10, 2022, after U.S. market close. The company, focused on developing therapeutics for neurological disorders, particularly epilepsy, will host a conference call at 4:30 PM ET to discuss the results. Participants can join using the provided dial-in numbers, with international access available. The event will also be streamed live on the company's investor website. Further information about their ongoing pipeline and developments can be found online.
Positive
- Xenon is focused on addressing high unmet medical needs in neurology, particularly epilepsy.
- The upcoming financial results presentation may provide insights into potential growth and advancements.
Negative
- None.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +3.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10, 2022.
Conference Call/Webcast Information:
| Date: | Tuesday, May 10, 2022 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-In Number: | 855-779-9075 |
| International Dial-In: | 631-485-4866 |
| Conference ID: | 2263884 |
The webcast will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.